Science and Research

An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.

Study details
Study-ID: NCT04816604, 2020-005169-15
DZL Disease Area: PH
Study Type: Interventional
DZL Role: DZL recruiting center
Funding: Externally - industry
DZL Participating Sites: TLRC
Start Date: 01.12.2021
Completion Date: 31.12.2027
Status: Closed
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.